Upscaling of lentiviral vector production by tangential flow filtration
- 20 May 2005
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 7 (10) , 1299-1310
- https://doi.org/10.1002/jgm.778
Abstract
Background HIV‐1‐derived vectors are promising tools for gene transfer into the brain. Application of these vectors for gene therapy or for the creation of animal models for neurodegenerative diseases requires standardization and upscaling of lentiviral vector production methods. Methods In this study, serum‐free HIV‐1 vector production was efficiently upscaled by use of cell factories and the introduction of tangential flow filtration (TFF) prior to centrifugation. Results Vector titers (TU/ml) and p24 values (pg p24/ml) for a serum‐free HIV‐1 vector produced in cell factories and using TFF prior to centrifugation were comparable to those of small‐scale productions. TFF allowed a 66‐fold concentration of the vectors with complete vector recovery. Further concentration of the vector (30‐fold) was achieved either by low‐speed centrifugation or by ultracentrifugation. Combination of TFF and ultracentrifugation resulted in a vector recovery of 90–100% and titers that increased 1800‐fold and 900‐fold for transducing units and p24 concentration, respectively. Conclusions With this new standardized method for lentiviral vector production and concentration, 1 ml of concentrated vector is routinely produced with titers of 109–1010 TU/ml starting from 2 l of cell‐culture medium. Moreover, stereotactic injection of this vector in mouse striatum resulted in a large transduced brain volume in the absence of any immune response. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 49 references indexed in Scilit:
- A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cellsNature, 2003
- Size-Exclusion Chromatography Purification of High-Titer Vesicular Stomatitis Virus G Glycoprotein-Pseudotyped Retrovectors for Cell and Gene Therapy ApplicationsHuman Gene Therapy, 2003
- Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐SynucleinBrain Pathology, 2003
- Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's diseaseProceedings of the National Academy of Sciences, 2003
- Production of clinical-grade recombinant adeno-associated virus vectorsCurrent Opinion in Biotechnology, 2002
- Replication-defective genomic herpes simplex vectors: design and productionCurrent Opinion in Biotechnology, 2002
- Viral receptors and vector purification: New approaches for generating clinical-grade reagentsNature Medicine, 1999
- Biochemical recovery and purification of gene therapy vectorsCurrent Opinion in Biotechnology, 1998
- HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathwayProceedings of the National Academy of Sciences, 1997
- HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulatorCell, 1995